GlassScriptPhysician profile
Marsha Ann Thomas
NPI 1528419694
$3,147.76
in general payments reported to CMS, 2019-2025
26 companies · $754 in 2025
The $754 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $462 · 2021: $88.98 · 2022: $632 · 2023: $785 · 2024: $426 · 2025: $754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,965.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,965.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $632.76 | 2022-2025 | Durysta, Lumigan, Alphagan P |
| Coopervision INC. | $453.27 | 2022-2024 | Myday Contact Lens, Misight Contact Lens, Synergeyes Contact Lens |
| Bausch & Lomb Americas INC. | $369.89 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Alcon Vision LLC | $299.84 | 2019-2025 | Rocklatan, Tryptyr |
| Sun Pharmaceutical Industries INC. | $220.59 | 2019-2025 | Cequa |
| Tarsus Pharmaceuticals, INC. | $178.41 | 2024-2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $172.17 | 2019-2023 | |
| Shire North American Group INC | $126.25 | 2019 | |
| Harrow Eye, LLC | $97.43 | 2024-2025 | Vevye |
| Amgen INC. | $97.20 | 2025 | Tepezza |
| Dompe US, INC. | $66.93 | 2025 | Oxervate |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $66.05 | 2019-2021 | |
| Oyster Point Pharma, INC. | $61.17 | 2022-2023 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $46.82 | 2021 | |
| Horizon Therapeutics Plc | $44.13 | 2022-2023 | Tepezza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eyevance Pharmaceuticals LLC | $33.96 | 2019 | |
| Glaukos Corporation | $30.39 | 2022 | |
| Biotissue Holdings INC. | $21.58 | 2023 | |
| Mallinckrodt Enterprises LLC | $19.63 | 2019 | |
| Aerie Pharmaceuticals, INC. | $17.91 | 2021 | |
| Allergan, INC. | $17.16 | 2022 | |
| Thea Pharma INC. | $16.95 | 2025 | Iyuzeh |
| Santen INC. | $15.68 | 2023 | Verkazia |
| Eyepoint US, INC. | $14.36 | 2019 | |
| Johnson & Johnson Surgical Vision, INC. | $13.71 | 2022 | |
| Rxsight INC | $13.52 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsha Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.